Baricitinib (Olumiant) for Severe Alopecia Areata

ABSTRACT

The oral Janus kinase (JAK) inhibitor baricitinib (Olumiant - Lilly), which was previously approved by the FDA for treatment of moderately to severely active rheumatoid arthritis and treatment of COVID-19 in certain hospitalized adults, has now been approved for treatment of severe alopecia areata in adults. Baricitinib is the first systemic treatment to be approved in the US for this indication.